Core Concept: What is SELEX? SELEX (Systematic Evolution of Ligands by EXponential Enrichment) is an iterative, in vitro selection process. It starts with a vast, random library of oligonucleotides (10^14 - 10^15 unique sequences) and, over multiple rounds, enriches for those that bind to the target. Standard Multi-Round SELEX Screening Service Workflow A full-service provider will typically manage the entire process, which can be broken down into key phases: Phase 1: Project Design & Target Preparation Target Consultation: Defining the target (e.g., protein, small molecule, cell, virus). Critical discussion of target purity, immobilization strategy, and selection conditions (buffer, temperature, counter-selection). Library Design: Selection of a random library (e.g., 40-nt random core with fixed primer sites). Options include DNA, RNA (requiring reverse transcription), or modified libraries (e.g., with 2'-F pyrimidines for nuclease resistance). Immobilization Strategy: The service provider will choose the best method: Immobilized Target: (Most common for proteins) Binding target to beads (streptavidin, Ni-NTA for His-tag) or columns. Counter-Selection: Using negative control surfaces (e.g., blank beads, related but undesired proteins) to subtract non-specific binders. Phase 2: The SELEX Cycle (Repeated 8-15 Rounds) This is the core iterative screening process. Each round consists of: Incubation: The oligonucleotide library is incubated with the target under defined conditions. Partitioning: Separation of…
Aptamers are short, single-stranded nucleic acids—typically ~20–100 nucleotides—that fold into defined 3D shapes and bind targets (proteins, small molecules, ions, cells) with high affinity and specificity. They are often described as “chemical antibodies,” but they behave differently: their binding comes from nucleic-acid folding + surface complementarity, and their performance is tightly linked to sequence chemistry, structure, and degradation pathways. When your core question is “DNA aptamers or RNA aptamers?”, the best answer is not a slogan. It’s a decision based on (1) structural needs, (2) stability environment, (3) manufacturability, (4) modification strategy, and (5) application constraints. 1) The Fundamental Difference: Structural Vocabulary vs Environmental Toughness RNA aptamers: richer folding vocabulary RNA has a 2′-OH group on the ribose, which expands hydrogen-bonding possibilities and supports a larger “structural vocabulary” (hairpins, internal loops, bulges, pseudoknots, complex tertiary contacts). In practice, this often means more diverse and intricate 3D conformations, which can translate into excellent binding performance for some targets. Takeaway: Choose RNA when the target demands highly nuanced shape recognition (e.g., challenging protein surfaces or structured RNA targets). DNA aptamers: generally more chemically stable and simpler DNA lacks the 2′-OH group and is typically more resistant to base-catalyzed…
What “SELEX Aptamer Selection” Means SELEX stands for Systematic Evolution of Ligands by Exponential Enrichment. In plain terms, SELEX aptamer selectionis an iterative laboratory workflow that starts with a huge pool of random DNA or RNA sequences and repeatedly enriches the fraction that binds a chosen target with high affinity and specificity. The “winners” are called aptamers—single-stranded nucleic acids that fold into 3D shapes capable of target recognition, often compared to “chemical antibodies,” but made by selection and synthesis rather than immune systems. Core Concept: Darwinian Evolution in a Test Tube SELEX is essentially variation + selection + amplification: Variation: Begin with a randomized oligonucleotide library (often ~10^13–10^16 unique sequences). Selection: Expose the library to the target; keep sequences that bind. Amplification: PCR (or RT-PCR for RNA workflows) amplifies binders to create the next-round pool. Increasing stringency: Each round tightens conditions (less target, harsher washes, more competitors), enriching the best binders over multiple cycles. Most conventional SELEX workflows run multiple rounds (often roughly 6–15) before candidates are sequenced and characterized. The Classic SELEX Workflow (Step-by-Step, With the “Why”) 1) Library design (the “starting universe”) A typical library contains: A random region (e.g., N30–N60) that can…
Aptamers are short, single-stranded nucleic acid molecules (DNA or RNA) that fold into specific 3D shapes and bind targets with high affinity and selectivity—often compared to how antibodies recognize antigens, but built from nucleic acids rather than proteins. Unlike a “generic DNA strand,” an aptamer’s function comes from structure: loops, stems, bulges, pseudoknots, and other motifs that create a binding surface matching a target’s geometry and chemistry. Targets can include proteins, peptides, small molecules, ions, and even whole cells (depending on the selection strategy). Why Aptamers Matter (and How They Differ From Antibodies) Aptamers are often described as “chemical antibodies,” but the differences are exactly why they’re valuable. Key advantages frequently highlighted Low immunogenicity (reduced risk of provoking immune responses) High stability and the ability to refold after denaturation in many cases Easy chemical synthesis (batch consistency, scalable manufacturing) Straightforward modification (labels, linkers, immobilization handles) Trade-offs you should know Nuclease sensitivity (especially RNA aptamers) can be a limitation in biological fluids unless stabilized. Selection bias can occur during discovery (e.g., PCR bias), meaning “best in the tube” isn’t always “best in reality.” Very high affinity does not automatically guarantee best real-world specificity; selection conditions matter. …
Ribosome Display is a cell-free (in vitro) display technology used to evolve and select peptides or proteins by keeping a physical connection between phenotype (the translated peptide/protein) and genotype (the encoding mRNA). Instead of relying on a living host (as in phage or yeast display), ribosome display uses a stalled translation complex so that the newly made polypeptide remains associated with the ribosome, which in turn remains associated with its mRNA—forming a non-covalent ternary complex that can be selected for binding or function. 1) What Ribosome Display Is (And Why the mRNA Link Matters) Display technologies work best when every “candidate molecule” can be traced back to the genetic information that produced it. In ribosome display, this tracking is achieved by stabilizing a complex often described as: nascent polypeptide – ribosome – mRNA Because the polypeptide and its mRNA remain physically connected through the ribosome, any selection step that enriches for a desired function (for example, binding to a target) can be followed by recovery of the encoding mRNA, conversion to cDNA, and amplification—creating an iterative loop of evolution entirely in vitro. 2) Core Mechanism: How the Ribosome “Holds” the Peptide to the mRNA The stalled translation complex…
mRNA Display is an in vitro selection and directed-evolution technology that physically couples a peptide (or protein) to the mRNA sequence that encodes it through a covalent bond. This genotype–phenotype “fusion” allows researchers to screen enormous molecular libraries and then recover the winning sequences by amplification, enabling fast, iterative optimization under tightly controlled experimental conditions. 1) The Core Idea: Genotype–Phenotype Coupling Without Cells Every selection technology needs a reliable way to keep “what a molecule does” attached to “the information that made it.” In mRNA Display, that attachment is literal: the newly made peptide becomes covalently linked to its own mRNA, producing a stable fusion that survives stringent washing and enrichment steps. This is a major conceptual advantage over systems where the linkage is non-covalent or depends on living cells for propagation. Because the entire workflow is performed in vitro, the experimenter can tune conditions (buffers, salts, temperature, denaturants, competitors) to match the target biology and the selection pressure they want to apply. 2) How the Covalent Link Is Formed: Puromycin at the 3′ End The “magic” reagent behind classic mRNA Display is puromycin, a molecule that mimics the 3′ end of an aminoacyl-tRNA. When puromycin is physically…